Physician profile
Ronald Brunk
NPI 1215561238
$3,403.46
in general payments reported to CMS, 2019-2025
26 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,803 · 2022: $1,107 · 2023: $164 · 2024: $165 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $447.74 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $410.71 | 2021-2023 | |
| Esperion Therapeutics, INC. | $370.00 | 2021-2022 | |
| Novo Nordisk INC | $309.80 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $293.15 | 2022 | |
| Amgen INC. | $280.37 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Lilly USA, LLC | $198.70 | 2021-2022 | |
| Abbvie INC. | $164.52 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $137.60 | 2021-2022 | |
| Eisai INC. | $117.13 | 2021-2022 | |
| Amarin Pharma, INC. | $115.13 | 2021 | |
| Corcept Therapeutics | $109.41 | 2024 | Korlym |
| Pfizer INC. | $74.34 | 2021-2023 | |
| Glaxosmithkline, LLC. | $72.37 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $64.08 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.37 | 2021-2023 | Spiriva Respimat |
| Acerus Pharmaceuticals Corporation | $29.04 | 2021 | |
| Edwards Lifesciences Corporation | $20.76 | 2025 | |
| Exact Sciences Corporation | $19.18 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $17.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.79 | 2021 | |
| Radius Health, INC. | $16.56 | 2024 | Tymlos |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.06 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.37 | 2025 | Xhance, Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2022 | |
| Fidia Pharma USA INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Brunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.